FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134748096> ?p ?o ?g. }

• W3134748096 endingPage "1005" @default.
• W3134748096 startingPage "1005" @default.
• W3134748096 abstract "Background: The Gustave Roussy Immune (GRIm)-Score takes into account neutrophil-to-lymphocyte ratio (NLR), serum albumin concentration and lactate dehydrogenase (LDH) and its prognostic value has been investigated in patients treated with immune check-point inhibitors (ICIs). To further assess the prognostic and predictive value of baseline GRIm-Score (GRImT0) in advanced non-small cell lung cancer (aNSCLC) patients, we separately investigated two cohorts of patients treated with first-line pembrolizumab or chemotherapy. We also investigated whether GRIm-Score at 45 days since treatment initiation (GRImT1) and GRIm-Score difference between the two timepoints may better predict clinical outcomes (GRImΔ = GRImT0 − GRImT1). Methods: We retrospectively evaluated 222 aNSCLC patients: 135 treated with pembrolizumab and 87 treated with chemotherapy as the first-line regimen. NLR, serum albumin and LDH concentrations were assessed at T0 and at T1. According to the GRIm-Score, patients were assigned 1 point if they had NLR > 6, LDH > upper limit normal or albumin < 3.5 g/dL. Patients with a GRIm-Score < 2 were considered as having a low Score. Results: In both cohorts, no difference in terms of overall survival (OS) between patients with low and high GRImT0 was found. Otherwise, median OS and progression free survival (PFS) of the low GRImT1 group were significantly longer than those of the high GRImT1 group in pembrolizumab-treated patients, but not in the CHT cohort (pembrolizumab cohort: low vs. high; median OS not reached vs. 9.2 months, p = 0.004; median PFS 10.8 vs. 2.3 months, p = 0.002). Patients receiving pembrolizumab with stable/positive GRImΔ had better OS (median OS not reached vs. 12.0 months, p < 0.001), PFS (median PFS 20.6 vs. 2.6 months, p < 0.001) and objective response rate (58.2% vs. 7.6%, p = 0.003) compared to patients with negative GRImΔ. Conclusion: Our data shown that GRImT1 and GRImΔ are more reliable peripheral blood biomarkers of outcome compared to GRImT0 in aNSCLC patients treated with pembrolizumab and might represent useful biomarkers to drive clinical decisions in this setting." @default.
• W3134748096 created "2021-03-15" @default.
• W3134748096 creator A5003036217 @default.
• W3134748096 creator A5007281746 @default.
• W3134748096 creator A5007575010 @default.
• W3134748096 creator A5009428093 @default.
• W3134748096 creator A5012937808 @default.
• W3134748096 creator A5016567527 @default.
• W3134748096 creator A5019053015 @default.
• W3134748096 creator A5020344479 @default.
• W3134748096 creator A5021264126 @default.
• W3134748096 creator A5025910178 @default.
• W3134748096 creator A5035173867 @default.
• W3134748096 creator A5056208054 @default.
• W3134748096 creator A5060954139 @default.
• W3134748096 creator A5062065961 @default.
• W3134748096 creator A5062803920 @default.
• W3134748096 creator A5067591586 @default.
• W3134748096 creator A5074937265 @default.
• W3134748096 creator A5082916894 @default.
• W3134748096 creator A5089368218 @default.
• W3134748096 creator A5091216622 @default.
• W3134748096 date "2021-03-02" @default.
• W3134748096 modified "2023-10-16" @default.
• W3134748096 title "The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab" @default.
• W3134748096 cites W2099725888 @default.
• W3134748096 cites W2130629599 @default.
• W3134748096 cites W2156353875 @default.
• W3134748096 cites W2157370605 @default.
• W3134748096 cites W2167191456 @default.
• W3134748096 cites W2309777334 @default.
• W3134748096 cites W2601854298 @default.
• W3134748096 cites W2737656823 @default.
• W3134748096 cites W2748446166 @default.
• W3134748096 cites W2769635882 @default.
• W3134748096 cites W2783295481 @default.
• W3134748096 cites W2784283849 @default.
• W3134748096 cites W2796582438 @default.
• W3134748096 cites W2898345296 @default.
• W3134748096 cites W2900661972 @default.
• W3134748096 cites W2910245285 @default.
• W3134748096 cites W2916562315 @default.
• W3134748096 cites W2921283714 @default.
• W3134748096 cites W2921656469 @default.
• W3134748096 cites W2925446385 @default.
• W3134748096 cites W2936066104 @default.
• W3134748096 cites W2947818354 @default.
• W3134748096 cites W2959622004 @default.
• W3134748096 cites W2978458313 @default.
• W3134748096 cites W2995043041 @default.
• W3134748096 cites W3017371859 @default.
• W3134748096 cites W3023951903 @default.
• W3134748096 cites W3029424640 @default.
• W3134748096 cites W3036354112 @default.
• W3134748096 cites W3036426939 @default.
• W3134748096 cites W3037411748 @default.
• W3134748096 cites W3042157765 @default.
• W3134748096 cites W3045548086 @default.
• W3134748096 cites W3048433505 @default.
• W3134748096 cites W3093354881 @default.
• W3134748096 cites W3111784361 @default.
• W3134748096 cites W3129132496 @default.
• W3134748096 doi "https://doi.org/10.3390/jcm10051005" @default.
• W3134748096 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7958321" @default.
• W3134748096 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33801320" @default.
• W3134748096 hasPublicationYear "2021" @default.
• W3134748096 type Work @default.
• W3134748096 sameAs 3134748096 @default.
• W3134748096 citedByCount "22" @default.
• W3134748096 countsByYear W31347480962021 @default.
• W3134748096 countsByYear W31347480962022 @default.
• W3134748096 countsByYear W31347480962023 @default.
• W3134748096 crossrefType "journal-article" @default.
• W3134748096 hasAuthorship W3134748096A5003036217 @default.
• W3134748096 hasAuthorship W3134748096A5007281746 @default.
• W3134748096 hasAuthorship W3134748096A5007575010 @default.
• W3134748096 hasAuthorship W3134748096A5009428093 @default.
• W3134748096 hasAuthorship W3134748096A5012937808 @default.
• W3134748096 hasAuthorship W3134748096A5016567527 @default.
• W3134748096 hasAuthorship W3134748096A5019053015 @default.
• W3134748096 hasAuthorship W3134748096A5020344479 @default.
• W3134748096 hasAuthorship W3134748096A5021264126 @default.
• W3134748096 hasAuthorship W3134748096A5025910178 @default.
• W3134748096 hasAuthorship W3134748096A5035173867 @default.
• W3134748096 hasAuthorship W3134748096A5056208054 @default.
• W3134748096 hasAuthorship W3134748096A5060954139 @default.
• W3134748096 hasAuthorship W3134748096A5062065961 @default.
• W3134748096 hasAuthorship W3134748096A5062803920 @default.
• W3134748096 hasAuthorship W3134748096A5067591586 @default.
• W3134748096 hasAuthorship W3134748096A5074937265 @default.
• W3134748096 hasAuthorship W3134748096A5082916894 @default.
• W3134748096 hasAuthorship W3134748096A5089368218 @default.
• W3134748096 hasAuthorship W3134748096A5091216622 @default.
• W3134748096 hasBestOaLocation W31347480961 @default.
• W3134748096 hasConcept C121608353 @default.
• W3134748096 hasConcept C126322002 @default.
• W3134748096 hasConcept C143998085 @default.
• W3134748096 hasConcept C181199279 @default.

• next